Natera (NTRA)

• Market cap: $22.5B
• 1 day: -2.20%
• 5 days: 1.53%
• 1 month: 36.81%
• 3 months: 44.83%
• 6 months: 53.61%
• Year to date: 174.84%
• 1 year: 192.00%
• 5 years: 370.63%
• 10 years: 648.37%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 3,293

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more call options, than puts

Call options by funds: $43.1M | Put options by funds: $24.7M

27% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 52

14% more capital invested

Capital invested by funds: $13.4B [Q2] → $15.3B (+$1.85B) [Q3]

3% more funds holding

Funds holding: 472 [Q2] → 486 (+14) [Q3]

9% less repeat investments, than reductions

Existing positions increased: 176 | Existing positions reduced: 193

3.69% less ownership

Funds ownership: 100.89% [Q2] → 97.19% (-3.69%) [Q3]

4% less funds holding in top 10

Funds holding in top 10: 25 [Q2] → 24 (-1) [Q3]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $135 21% downside
• Avg. target: $160 6% downside
• High target: $200 18% upside

12 analyst ratings

• positive: 12 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler David Westenberg 67% 1-year accuracy 10 / 15 met price target	18% upside $200	Overweight Maintained	18 Nov 2024
Morgan Stanley Tejas Savant 0% 1-year accuracy 0 / 6 met price target	3% upside $176	Overweight Maintained	14 Nov 2024
TD Cowen Dan Brennan 57% 1-year accuracy 16 / 28 met price target	3% upside $175	Buy Maintained	13 Nov 2024
Craig-Hallum Alexander Nowak 89% 1-year accuracy 8 / 9 met price target	8% downside $157	Buy Maintained	13 Nov 2024
JP Morgan Julia Qin 100% 1-year accuracy 4 / 4 met price target	6% downside $160	Overweight Maintained	13 Nov 2024